Novo Nordisk reports strong demand for diabetes treatments in China

Global healthcare company Novo Nordisk has revealed that demand for its diabetes treatments remains strong in China.

According to Jesper Brandgaard, chief financial officer at the firm, it has seen an "underlining significant growth" in the number of people getting diabetes in the Asian nation.

As a result, its products have been sought after in the Chinese market.

However, Mr Brandgaard admitted to CNBC that the possibility of a slowdown in emerging markets due to oil prices remains a "significant concern".

"The ability to pay could be influenced by oil prices, because to a large degree it could often be the governments that are purchasing the goods that we're selling," he commented.

Mr Brandgaard added that oil prices of around 50 dollars a barrel would be more comfortable to his company than the current level.

More than a quarter of chief financial officers in Europe polled by CNBC have admitted that emerging markets represent the biggest risks to their businesses.